Senasa, the Argentine health agency, has authorized Tecnovax to register and commercialize a new vaccine against foot-and-mouth disease, marking a significant development for the agricultural sector in Argentina. This decision comes after nearly two years of extensive procedures and compliance with various technical and regulatory requirements. Tecnovax reported that throughout this period, the company provided all necessary guarantees concerning the vaccine’s quality, safety, and efficacy to meet the current legal and regulatory framework.

The vaccine in question is a bivalent product developed by the Brazilian laboratory Ourofino Saúde Animal. With this new authorization, Tecnovax aims to enhance the availability of vaccines in Argentina's livestock health campaign, contributing to improved animal health and potentially better economic outcomes for farmers affected by foot-and-mouth disease.

This approval can be seen as a critical step in strengthening Argentina's agricultural health strategies, especially considering the impact of foot-and-mouth disease on livestock industries. As the country navigates through agricultural challenges, the introduction of this vaccine could play a pivotal role in protecting livestock from disease outbreaks, thereby securing the livelihoods of many farmers and supporting the overall economy.